Kimberly-Clark Corp. shares fell the most in a quarter century after agreeing to buy Kenvue Inc., whose biggest product, Tylenol, is in the crosshairs of the White House.

Kimberly-Clark Corp. will acquire Tylenol maker Kenvue Inc. in a cash and stock deal valued at almost $49 billion the two companies announced Nov. 3. The companies in news releases billed the combination as a merger of two iconic American companies and a complementary portfolio of consumer health and personal care products that includes 10 $1 billion-plus brands.

Kenvue’s stock, which had hit a record low in recent weeks, was headed for its best day ever, while Kimberly-Clark’s stock tumbled.

Huggies’ maker Kimberly-Clark announced Monday it’s buying Tylenol’s parent company Kenvue in a nearly $50 billion deal, creating a consumer product conglomerate.

Kimberly-Clark is buying Tylenol maker Kenvue for nearly $50 billion, and Wall Street isn’t too fond of the deal. And for good reason. The cash-and-stock transaction, announced Monday, values Kenvue at an enterprise value of about $48.

Big brands and big money - Kimberly-Clark is buying Kenvue in a nearly $50 billion cash and stock deal. That would put Huggies, Kleenex, Band-Aid, Neutrogena and Tylenol all under one roof. It’s one of the biggest deals on Wall Street this year and a major move for Kimberly-Clark,

Kenvue announced the merger this morning. For $48.7 billion, Kimberly-Clark (which is primarily a paper goods manufacturer, producing everything from Hug

Kenvue shareholders are cheering Monday as shares are surging ~16% in Monday trading following the announcement that Kimberly-Clark (KMB) will acquire the consumer healthcare products company for about $48.